DGIdb - PTGS1 Gene Record

PTGS1 5742 Druggable Genome

Alternate Names:

5742
PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1
PTGS1
COX1
COX3
PCOX1
PES-1
PGG/HS
PGHS-1
PGHS1
PHS1
PTGHS
176805
9604
ENSG00000095303
OTTHUMG00000020605
PA24346
Prostaglandin G/H synthase 1
Cyclooxygenase-1
Prostaglandin H2 synthase 1
COX-1
PGH synthase 1
PHS 1
P23219
PGH1_HUMAN
1375
BE0000017
PROSTAGLANDIN G/H SYNTHASE 1 PRECURSOR (EC 1.14.99.1) (CYCLOOXYGENASE- 1) (COX-1) (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1) (PROSTAGLANDIN H2 SYNTHASE 1) (PGH SYNTHASE 1) (PGHS-1) (PHS 1). [SOURCE:UNIPROT/SWISSPROT;ACC:P23219]
T60529

Gene Info:

Target Subclass	1.14.99.1
Target Main Class	Enzymes
Target Class	Enzymes
Target Subclass	EC:1.14.99.1
Human Readable Name	DRUGGABLE GENOME
Interpro Acc	IPR002007
Interpro Short Name	Haem_peroxidase_animal
Uniprot Evidence	1: Evidence at protein level
Interpro Type	Family
Uniprot Status	Swiss-Prot
Interpro Name	Haem peroxidase, animal
Gene Biotype	PROTEIN_CODING
GuideToPharmacology Gene Category Name	Cyclooxygenase
GuideToPharmacology Gene Category ID	269

(10 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME
ENZYME

Publications:

Hinz et al., 2008, Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man., FASEB J.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Sinning C et al., 2008, New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide., J Med Chem
Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.
Llorens et al., 2002, Differential binding mode of diverse cyclooxygenase inhibitors., J. Mol. Graph. Model.
Bender et al., 2007, Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure., ChemMedChem
Warner et al., 1999, Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis., Proc. Natl. Acad. Sci. U.S.A.
Loll et al., 1996, Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site., Biochemistry
Morton et al., 2005, Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis., Res. Vet. Sci.
Beretta et al., 2005, COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis., Pharmacol. Res.
Zitova et al., 2010, Analysis of activity and inhibition of oxygen-dependent enzymes by optical respirometry on the LightCycler system., Anal. Biochem.
Yu et al., 2013, Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro., Biopharm Drug Dispos
Martić et al., 2004, Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors., Eur J Med Chem
Vitale P et al., 2013, Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors., J Med Chem
Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
Gupta et al., 2004, Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors., Bioorg. Med. Chem. Lett.
Hillarp, 2004, [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]., Lakartidningen
Patrignani, 2003, Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease., Thromb. Res.
Chavez et al., 2003, Valdecoxib: a review., Clin Ther
Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
Lepäntalo A et al., 2006, Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients., Thromb Haemost
Verschuren JJ et al., 2013, Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction., Int J Cardiol
Kundu et al., 2005, Cyclooxygenase inhibitors modulate NK activities that control metastatic disease., Cancer Immunol. Immunother.
Higuchi et al., 2004, Indomethacin, but not Helicobacter pylori, inhibits adaptive relaxation in isolated guinea-pig stomach., Drugs Exp Clin Res
Bobadilla L et al., 2005, Effect of pregnancy on the roles of nitric oxide and prostaglandins in 5-hydroxytryptamine-induced contractions in rat isolated thoracic and abdominal aorta., Clin. Exp. Pharmacol. Physiol.
Christ AN et al., 2010, Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases., J Med Chem
Moth et al., 2005, Stereoselective binding of indomethacin ethanolamide derivatives to cyclooxygenase-1., J. Med. Chem.
Hanna MM, 2012, New pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidines: synthesis, 2D-QSAR, anti-inflammatory, analgesic and ulcerogenicity studies., Eur J Med Chem
Blanco et al., 1999, Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes., J. Rheumatol.
Fornai et al., 2005, Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice., Gut
Ottonello et al., 2009, Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway., Br. J. Pharmacol.
Kawai, 1998, Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration., Inflamm. Res.
Kean, 2004, Oxaprozin: kinetic and dynamic profile in the treatment of pain., Curr Med Res Opin
Zhou et al., 2009, Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug., Biol. Pharm. Bull.
Yood et al., 2006, The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy., Pharmacoepidemiol Drug Saf
Gamache et al., 2000, Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy., Inflammation
Young et al., 1996, Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production., Inflamm. Res.
Cappon et al., 2003, Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure., Birth Defects Res. B Dev. Reprod. Toxicol.
Chen et al., 2005, Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors., Bioorg. Med. Chem.
James et al., 2007, Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: a case study of system failure., Lipids
Brutzkus JC et al., 2020, Naproxen,
Brune et al., Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective., Clin. Exp. Rheumatol.
Schmidt et al., 1991, Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F)., J. Biol. Chem.
Josephs et al., 1999, Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility., J. Surg. Res.
Stevenson, 2004, Aspirin and NSAID sensitivity., Immunol Allergy Clin North Am
Poggi et al., 2006, Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus., J Clin Pharmacol
Wang H et al., 1999, Antioxidant and antiinflammatory activities of anthocyanins and their aglycon, cyanidin, from tart cherries., J Nat Prod
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Wiggins et al., 2009, Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis., Expert Opin Drug Metab Toxicol
Cipollone et al., 1995, Effects of nabumetone on prostanoid biosynthesis in humans., Clin. Pharmacol. Ther.
Bensen et al., 1998, Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis., Can Fam Physician
Takeuchi et al., 2006, Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease., Clin. Gastroenterol. Hepatol.
Giuliano et al., 2001, Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation., Eur. J. Pharmacol.
Gates BJ et al., 2005, Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety., Expert Opin Pharmacother
Panara et al., 1999, Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects., J. Pharmacol. Exp. Ther.
Bekker A et al., 2018, Meloxicam in the management of post-operative pain: Narrative review., J Anaesthesiol Clin Pharmacol
Glaser et al., 1995, Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1., Eur. J. Pharmacol.
Riendeau et al., 1997, Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor., Br. J. Pharmacol.
Campbell et al., 2002, The effects of cyclo-oxygenase inhibitors on bile-injured and normal equine colon., Equine Vet. J.
Hirate et al., 2006, Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors., Neurosci. Res.
Wilson et al., 2004, Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs., Am. J. Vet. Res.
Raju et al., 2002, Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam., Mol. Cell. Biochem.
Bugajski et al., 2001, Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion., J. Physiol. Pharmacol.
Fackovcova et al., 2000, Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance., Bratisl Lek Listy
Veiga et al., 2004, Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats., Life Sci.
Berry et al., 1983, Antrafenine, naproxen and placebo in osteoarthritis: a comparative study., Br. J. Rheumatol.
Hassan et al., 1982, A comparison of antrafenine and aspirin on platelet aggregation and frusemide-induced diuresis., Postgrad Med J
Koeberle A et al., 2014, SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase., J Med Chem
Kurahashi et al., 2001, Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites., J. Cardiovasc. Pharmacol.
Rieke et al., 1999, The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors., J. Biol. Chem.
Hewett et al., 2000, Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture., J. Pharmacol. Exp. Ther.
Klegeris et al., Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity., Neurobiol. Aging
Basselin et al., 2007, Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats., Neurochem. Res.
Dröge et al., Alternative splicing of cyclooxygenase-1 mRNA in the human iris., Ophthalmic Res.
Nivsarkar et al., Cyclooxygenase inhibitors: a novel direction for Alzheimer's management., Pharmacol Rep
Waterbury et al., 2006, Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium., Curr Med Res Opin
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.
Cheng et al., 2002, Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene., J. Physiol. Pharmacol.
Soriano et al., 1999, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines., Cancer Res.
Cheng et al., 2003, Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27)., Eur. J. Pharmacol.
Lim et al., 1999, Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines., Biochem. Pharmacol.
Lúcio et al., 2006, Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity., Med Chem
Kothekar et al., Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study., Indian J. Biochem. Biophys.
Lora et al., 1997, Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin., Prostaglandins Leukot. Essent. Fatty Acids
Yamada et al., 1997, Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages., J. Pharmacol. Exp. Ther.
Ozgocmen et al., 2005, In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis., Ann. Clin. Lab. Sci.
Zúñiga et al., 2003, Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo., Biol. Res.
Parsadaniantz et al., 2000, Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat., J. Neuroendocrinol.
Levoin et al., 2004, Elucidation of the mechanism of inhibition of cyclooxygenases by acyl-coenzyme A and acylglucuronic conjugates of ketoprofen., Biochem. Pharmacol.
Dionne et al., Analgesia and COX-2 inhibition., Clin. Exp. Rheumatol.
Uzan, 2005, The unexpected side effects of new nonsteroidal anti-inflammatory drugs., Expert Opin Emerg Drugs
Bosch-Marcè et al., 1999, Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites., Gastroenterology
Blais et al., 2005, Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli., J. Neurochem.
Lashbrook et al., 1999, Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats., Pain
Kämpfer et al., 2003, Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair., J. Invest. Dermatol.
Hinz et al., 2003, Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac., Clin. Pharmacol. Ther.
Calkin et al., 2002, Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2., J. Clin. Endocrinol. Metab.
Kirchheiner et al., 2003, Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans., Br J Clin Pharmacol
Nurtjahja-Tjendraputra et al., 2003, Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger., Thromb. Res.
Kennedy et al., 2003, Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility., Reprod. Biol. Endocrinol.
Capasso, 1999, Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues., Neuropharmacology
Capasso et al., 1997, Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum., Eur. J. Pharmacol.
Burdan et al., 2005, Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL:(WI)WUBR rats., Toxicology
Das, 2005, Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?, J Assoc Physicians India
Levin et al., 2002, Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2., Biochem. J.
Malkowski et al., 2001, Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1., J. Biol. Chem.
Das, 2005, COX-2 inhibitors and metabolism of essential fatty acids., Med. Sci. Monit.
Thuresson et al., 2001, Mutational and X-ray crystallographic analysis of the interaction of dihomo-gamma -linolenic acid with prostaglandin endoperoxide H synthases., J. Biol. Chem.
Ringbom T et al., 1998, Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis., J Nat Prod
Cryer et al., 1998, Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs., Am. J. Med.
Sinniah et al., 2001, Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid., Clin. Nephrol.
Gierse et al., 1995, Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase., Biochem. J.
Joo et al., 2006, Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models., Mol. Pharmacol.
Laudanno et al., 1998, [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats]., Acta Gastroenterol. Latinoam.
Yang et al., 2004, Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells., J. Lipid Res.
Vecchio et al., 2010, Structural basis of fatty acid substrate binding to cyclooxygenase-2., J. Biol. Chem.
Lee et al., 2003, Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids., J. Lipid Res.
Machida et al., 2005, Docosahexaenoic acid enhances cyclooxygenase-2 induction by facilitating p44/42, but not p38, mitogen-activated protein kinase activation in rat vascular smooth muscle cells., J. Pharmacol. Sci.
Kammerl et al., 2001, Inhibition of COX-2 counteracts the effects of diuretics in rats., Kidney Int.
Gao LC et al., 2015, Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients., Eur J Clin Pharmacol
Talbot et al., 2011, Cigarette smoke-induced kinin B1 receptor promotes NADPH oxidase activity in cultured human alveolar epithelial cells., Peptides
Shiels et al., 2000, Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea., Allerg Immunol (Paris)
Meade et al., 1993, Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs., J. Biol. Chem.
Pérez-Vizcaíno et al., 2002, Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity., Am. J. Physiol. Lung Cell Mol. Physiol.
Kalgutkar et al., 2000, Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors., Proc. Natl. Acad. Sci. U.S.A.
Dominguez et al., 1985, Effects of triflusal in patients with prosthetic heart valves., Clin Ther
Anninos et al., Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness., Hellenic J Cardiol
Simon, 2004, Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs., Curr Allergy Asthma Rep
Nizankowska et al., 1990, Salicylate pre-treatment attenuates intensity of bronchial and nasal symptoms precipitated by aspirin in aspirin-intolerant patients., Clin. Exp. Allergy
Schwartz, 2006, Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility., Adv Clin Chem
McGarry et al., 2005, Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway., Filaria J
Renner et al., 2010, Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials., Contraception
Berg et al., 1999, The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro., Inflamm. Res.
Rose et al., 2004, Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study)., Clin Drug Investig
Bianchi et al., 2002, Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail., Pharmacol. Res.
Kurbel et al., 1999, Minoxidil and male-pattern alopecia: a potential role for a local regulator of sebum secretion with vasoconstrictive effects?, Med. Hypotheses
Michelet et al., 1997, Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect., J. Invest. Dermatol.
Gaffar et al., 1995, The effect of triclosan on mediators of gingival inflammation., J. Clin. Periodontol.
Warner et al., 2006, Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2., FASEB J.
Blobaum et al., 2007, Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib., J. Biol. Chem.
Capone et al., Clinical pharmacology of selective COX-2 inhibitors., Int J Immunopathol Pharmacol
Esser et al., 2005, Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2., Br. J. Pharmacol.
Jermany et al., 2005, Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects., J Clin Pharmacol
Graham et al., 2003, Mechanisms of action of paracetamol and related analgesics., Inflammopharmacology
Sun et al., 2005, P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function., Am. J. Physiol. Renal Physiol.
Moon et al., 2004, Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases., Neurosci. Lett.
Liu et al., 2006, Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice., Anesth. Analg.
Celik et al., 2005, Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance., J Asthma
Riendeau D et al., 2004, Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2., Bioorg Med Chem Lett
Lees P et al., 1998, Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation., Vet J
McKellar QA et al., 1994, Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships., Eur J Pharmacol
Tokola RA et al., 1984, Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid., Br J Clin Pharmacol
Ashraf Z et al., 2016, Synthesis, Bioevaluation and Molecular Dynamic Simulation Studies of Dexibuprofen-Antioxidant Mutual Prodrugs., Int J Mol Sci
Legrand E, 2004, Aceclofenac in the management of inflammatory pain., Expert Opin Pharmacother
Ibeas Bih C et al., 2015, Molecular Targets of Cannabidiol in Neurological Disorders., Neurotherapeutics
Brogden RN et al., 1975, Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses., Drugs
Gresele P et al., 2006, Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders., Cardiovasc Drug Rev
Corazzi T et al., 2005, Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016)., J Pharmacol Exp Ther
Esteve J et al., 1988, Pharmacological profile of droxicam., Gen Pharmacol
Ouellet et al., 1995, Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms., Biochem. J.
Levy G, 1980, Clinical pharmacokinetics of salicylates: a re-assessment., Br J Clin Pharmacol

SUPROFEN PTGS1

Interaction Score: 2.84

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
11885959 11752352 17477341 10377455 8652509

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
CHEMBL1234916 PTGS1

Interaction Score: 2.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235 17139284 17016423

Sources:
DrugBank
BROMOACETIC ACID PTGS1

Interaction Score: 2.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235 17139284 17016423

Sources:
DrugBank
SALSALATE PTGS1

Interaction Score: 2.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
1680855 10452868 11752352 15242723

Sources:
TEND TdgClinicalTrial TTD DrugBank
DIHOMO-GAMMA-LINOLENIC ACID PTGS1

Interaction Score: 1.81

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16190133 11939906 11477109 15990700 11752352 11121413

Sources:
DrugBank
BROMFENAC PTGS1

Interaction Score: 1.81

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Bromfenac

Novel drug target Established target

Trial Name ISV-101

PMIDs:
16846546 11752352

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology
NCX-4016 PTGS1

Interaction Score: 1.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16961726 16144976

Sources:
DrugBank
MAGNESIUM SALICYLATE PTGS1

Interaction Score: 1.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
15035793 15840771 14746879 16368818 15871445

Sources:
DrugBank
KETOROLAC PTGS1

Interaction Score: 1.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ketorolac tromethamine ophthalmic solution,Acuvail

Novel drug target Established target

Trial Name ROX-828

PMIDs:
11695255 16262557 10220509 16277613 10422661

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology
OXAPROZIN PTGS1

Interaction Score: 1.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
19338579 9831331 15324530 19952416 17024689

Sources:
DrugBank GuideToPharmacology ChemblInteractions
NEPAFENAC PTGS1

Interaction Score: 1.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
10850857

Sources:
TEND TdgClinicalTrial DrugBank ChemblInteractions
TOLMETIN PTGS1

Interaction Score: 1.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
14613550 10465690 9253954 16182428

Sources:
TEND TdgClinicalTrial DrugBank
CHEMBL27784 PTGS1

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235

Sources:
DrugBank
CHEMBL24957 PTGS1

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235

Sources:
DrugBank
CHOLINE MAGNESIUM TRISALICYLATE PTGS1

Interaction Score: 1.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
14680616 2083404 17131625

Sources:
DrugBank
IODOINDOMETHACIN PTGS1

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235

Sources:
DrugBank
ANTRAFENINE PTGS1

Interaction Score: 1.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17541796 6342700 7088753

Sources:
DrugBank
ETODOLAC PTGS1

Interaction Score: 1.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name VT-122

Novel drug target Established target

PMIDs:
8566109 9146894 12358053 16473424 15198222

Sources:
TEND TdgClinicalTrial DrugBank
BALSALAZIDE PTGS1

Interaction Score: 1.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name balsalazide disodium,Colazal, Giazo

PMIDs:
12950415 11752352 17139284 17016423 19743890

Sources:
TdgClinicalTrial TTD DrugBank
FLURBIPROFEN PTGS1

Interaction Score: 0.95

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
11811354 10358065 10773011 12392782 17562170 12711844 19066416

Sources:
TEND DrugBank GuideToPharmacology ChemblInteractions
TIAPROFENIC ACID PTGS1

Interaction Score: 0.86

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
14987823 14741265 15575422 14592549

Sources:
DrugBank
KETOPROFEN PTGS1

Interaction Score: 0.86

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ketoprofen in Transfersome gel, IDEA-033,Diractin

Novel drug target Established target

Trial Name ketoprofen transdermal patch, EN3269

PMIDs:
11811354 14987823 14513718 10929089 15476667

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
TENOXICAM PTGS1

Interaction Score: 0.83

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17017983 11563332 9175172 9152412 15943176

Sources:
TEND TdgClinicalTrial DrugBank
DIFLUNISAL PTGS1

Interaction Score: 0.72

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Trial Name CRx-401

PMIDs:
8737748 12852483 15755648

Sources:
TEND TdgClinicalTrial DrugBank ChemblInteractions
LUMIRACOXIB PTGS1

Interaction Score: 0.62

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16403783 17434872 14552704 15655513 16172182

Sources:
DrugBank
MECLOFENAMIC ACID PTGS1

Interaction Score: 0.62

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
11094641 8454631 12225961 15198222 10639181

Sources:
DrugBank
MELOXICAM PTGS1

Interaction Score: 0.62

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
16197363 10381787 10381057 30774225

Sources:
DrugBank GuideToPharmacology
CHEMBL173562 PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
7437270

Sources:
DrugBank
DROXICAM PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
3278945

Sources:
DrugBank
LOXOPROFEN PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
14980665

Sources:
DrugBank
(+)-EPICATECHIN PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
LORNOXICAM PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
20399943 10450786 17516707 11846620

Sources:
DrugBank
DIETHYLCARBAMAZINE PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
15932636

Sources:
DrugBank
PHENACETIN PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11752352

Sources:
DrugBank
NAPROXCINOD PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TdgClinicalTrial GuideToPharmacology ChemblInteractions
CARPROFEN PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
15939622

Sources:
DrugBank
GINGER PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14693173

Sources:
NCI
NABUMETONE PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
7554708 9481468 16469680 11525777

Sources:
TEND TdgClinicalTrial DrugBank
E163 PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10075763

Sources:
DTC
FENOPROFEN PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

Specific Action of the Ligand Inhibition

PMIDs:
17050798

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology
ANTIPYRINE PTGS1

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
11695253

Sources:
DrugBank
PIROXICAM PTGS1

Interaction Score: 0.47

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Cyclooxygenase inhibitor

Specific Action of the Ligand Inhibition

PMIDs:
11952155 11785774 11153163 15464832 10381057

Sources:
TEND TTD DrugBank GuideToPharmacology ChemblInteractions
MEFENAMIC ACID PTGS1

Interaction Score: 0.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
9626023 11316248 7832763 16223958 9773153

Sources:
DrugBank ChemblInteractions
ACECLOFENAC PTGS1

Interaction Score: 0.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
15163279

Sources:
DrugBank
LATANOPROST PTGS1

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25339146

Sources:
PharmGKB
ICOSAPENT PTGS1

Interaction Score: 0.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16190133 14993240 20463020 12562875 11477109 15990700 16141635

Sources:
DrugBank
NAPROXEN PTGS1

Interaction Score: 0.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Cyclooxygenase inhibitor

Trial Name MT 100

PMIDs:
17541796 30247840

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
DIPYRONE PTGS1

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11752352

Sources:
DrugBank
TRIFLUSAL PTGS1

Interaction Score: 0.31

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
3838919 19465361

Sources:
DrugBank
TROLAMINE SALICYLATE PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
ACEMETACIN PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
BENDAZAC PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
AMINOSALICYLATE SODIUM PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
IMRECOXIB PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
DICLOFENAC EPOLAMINE PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
VB-201 PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name VB-201

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
BROMFENAC SODIUM PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
FENOPROFEN CALCIUM PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
GW-406381 PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology
FLURBIPROFEN SODIUM PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
FENBUFEN PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
NAPROXEN ETEMESIL PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DICLOFENAC POTASSIUM PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
IBUPROFEN SODIUM PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
AMINOSALICYLATE POTASSIUM PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CURCUMIN PYRAZOLE PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24920381

Sources:
DTC
OXAPROZIN POTASSIUM PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
IBUPROFEN LYSINE PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PHENYLBUTAZONE PTGS1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
15563928 15939622 19849999

Sources:
DrugBank GuideToPharmacology ChemblInteractions
DICLOFENAC PTGS1

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
12713596 12966366 12852704 11752352 12414874 12534640

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
SULINDAC PTGS1

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
10372826 12512695 10626810 12586211 10484067

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
HYPERFORIN PTGS1

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
11752352

Sources:
DrugBank
IBUPROFEN PTGS1

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name HZT-501, ibuprofen + famotidine,Duexa

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
23536207 14987823 23651359 25502615 14741265 15575422 14592549 12852704 11752352

Sources:
TEND DTC PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
TOLFENAMIC ACID PTGS1

Interaction Score: 0.19

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
9638074 8200415 6691890

Sources:
DrugBank
PHENYL SALICYLATE PTGS1

Interaction Score: 0.17

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
BUFEXAMAC PTGS1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
1204506

Sources:
DrugBank
KETOROLAC TROMETHAMINE PTGS1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TOLMETIN SODIUM PTGS1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
NAPROXEN SODIUM PTGS1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
INDOMETHACIN PTGS1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
15891886 23651359 15700751 15743404 20684598 15887968 22818041 10381057 15831902

Sources:
TEND DTC DrugBank GuideToPharmacology ChemblInteractions
MESALAMINE PTGS1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name MAX-002

Novel drug target Established target

Trial Name mesalamine,Pentasa, Canasa, Asacol

PMIDs:
12950415 11752352

Sources:
TEND TdgClinicalTrial TTD DrugBank ChemblInteractions
MINOXIDIL PTGS1

Interaction Score: 0.16

Interaction Types & Directionality:

inducer (activating)

Interaction Info:

PMIDs:
10616041 9008235 7560228

Sources:
DrugBank
ARACHIDONIC ACID PTGS1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235 17139284 17016423

Sources:
DrugBank
TALNIFLUMATE PTGS1

Interaction Score: 0.13

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
PROPACETAMOL PTGS1

Interaction Score: 0.13

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
DEXKETOPROFEN PTGS1

Interaction Score: 0.13

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
OLSALAZINE SODIUM PTGS1

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SC-560 PTGS1

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
GuideToPharmacology
DERSALAZINE PTGS1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name dersalazine sodium

PMIDs:
None found

Sources:
TdgClinicalTrial
BISMUTH SUBSALICYLATE PTGS1

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BALSALAZIDE DISODIUM PTGS1

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
ACETAMINOPHEN PTGS1

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
17884974 11752352 19053765

Sources:
TEND DTC TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
NIFLUMIC ACID PTGS1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21600945

Sources:
DrugBank
FLUFENAMIC ACID PTGS1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7864817

Sources:
DrugBank
DEXTROSE PTGS1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10592235 17139284 17016423

Sources:
DrugBank
DICLOFENAC SODIUM PTGS1

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
URSOLIC ACID PTGS1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9784154

Sources:
DTC
DEXIBUPROFEN PTGS1

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
28009827

Sources:
DrugBank
MECLOFENAMATE SODIUM PTGS1

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
SULFASALAZINE PTGS1

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Cyclooxygenase inhibitor

Novel drug target Established target

PMIDs:
12950415

Sources:
TdgClinicalTrial DrugBank ChemblInteractions
ASPIRIN PTGS1

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
20938371 23651359 16493486 22940005

Sources:
TEND DTC PharmGKB GuideToPharmacology ChemblInteractions
CLOPIDOGREL PTGS1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22940005

Sources:
PharmGKB
OXYPHENBUTAZONE PTGS1

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
NIMESULIDE PTGS1

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
GuideToPharmacology
HYDROCHLOROTHIAZIDE PTGS1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11703585

Sources:
NCI
CANNABIDIOL PTGS1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
26264914

Sources:
DrugBank
NABIXIMOLS PTGS1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
26264914

Sources:
DrugBank
CURCUMIN PTGS1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24920381

Sources:
DTC TTD
RESVERATROL PTGS1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
11752352

Sources:
DrugBank
CELECOXIB PTGS1

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

Ensembl: ENSG00000095303
- Version: 101_38
Alternate Names:

PTGS1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: P23219
- Version: 01-August-2011
Alternate Names:

PGH1_HUMAN Uniprot Id

PTGS1 Gene Symbol

5742 Entrez Gene Id

Gene Info:

Target Subclass 1.14.99.1

Target Main Class Enzymes

Publications:

RussLampel: ENSG00000095303

Version: 26-July-2011

Alternate Names:

PROSTAGLANDIN G/H SYNTHASE 1 PRECURSOR (EC 1.14.99.1) (CYCLOOXYGENASE- 1) (COX-1) (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1) (PROSTAGLANDIN H2 SYNTHASE 1) (PGH SYNTHASE 1) (PGHS-1) (PHS 1). [SOURCE:UNIPROT/SWISSPROT;ACC:P23219] Description

ENSG00000095303 Ensembl Gene Id

PTGS1 Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

HopkinsGroom: P23219
- Version: 11-September-2012
Alternate Names:

ENSG00000095303 Ensembl Gene Id

PTGS1 Uniprot Gene Name

PGH1_HUMAN Uniprot Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Interpro Acc IPR002007

Interpro Short Name Haem_peroxidase_animal

Gene Categories:

DRUGGABLE GENOME

Publications:
TdgClinicalTrial: P23219
- Version: January-2014
Alternate Names:

PTGS1 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:1.14.99.1

Publications:
GuideToPharmacology: 5742
- Version: 29-September-2020
Alternate Names:

9604 HUGO Gene ID

9604 HUGO Gene Symbol

prostaglandin-endoperoxide synthase 1 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name Cyclooxygenase

GuideToPharmacology Gene Category ID 269

Gene Categories:

ENZYME

Publications:

PharmGKB: PTGS1

Version: 18-August-2020

Alternate Names:

PA24346 PharmGKB ID

Gene Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

St Germaine CG et al., 2010, Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs., Am J Cardiol

Gao LC et al., 2015, Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients., Eur J Clin Pharmacol

DrugBank: BE0000017

Version: 5.1.7

Alternate Names:

PTGS1 DrugBank Gene Name

P23219 UniProt Accession

5742 Entrez Gene Id

Gene Info:

Publications:

Das, 2005, Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?, J Assoc Physicians India

Yang et al., 2004, Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells., J. Lipid Res.

Vecchio et al., 2010, Structural basis of fatty acid substrate binding to cyclooxygenase-2., J. Biol. Chem.

TTD: Prostaglandin G/H synthase 1
- Version: 2020.06.01
Alternate Names:

COX-1 TTD Gene Abbreviation

T60529 TTD Target ID

Gene Info:

Publications:

Cohen MP et al., 2013, Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats., Physiol Rep

NCI: PTGS1

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Kammerl et al., 2001, Inhibition of COX-2 counteracts the effects of diuretics in rats., Kidney Int.

Giannitrapani et al., 2007, Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C., Eur J Gastroenterol Hepatol

Nurtjahja-Tjendraputra et al., 2003, Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger., Thromb. Res.

DTC: PTGS1

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Vitale P et al., 2013, Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors., J Med Chem

Wang H et al., 1999, Antioxidant and antiinflammatory activities of anthocyanins and their aglycon, cyanidin, from tart cherries., J Nat Prod

Sinning C et al., 2008, New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide., J Med Chem

ChemblInteractions: COX1
- Version: chembl_23
Alternate Names:

COX1 GENE_SYMBOL

PTGS1 GENE_SYMBOL

Prostaglandin G/H synthase 1 UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000095303
- Version: 31-May-2017
Alternate Names:

ENSG00000095303 Gene Symbol

PTGS1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Pharos: PTGS1
- Version: 03-September-2020
Alternate Names:

Prostaglandin G/H synthase 1 Gene Name

P23219 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:

Mechanism of Interaction	Cyclooxygenase inhibitor
Direct Interaction	yes
Specific Action of the Ligand	Inhibition

Trial Name	Bromfenac
Novel drug target	Established target
Trial Name	ISV-101

Trial Name	ketorolac tromethamine ophthalmic solution,Acuvail
Novel drug target	Established target
Trial Name	ROX-828

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Trial Name	ketoprofen in Transfersome gel, IDEA-033,Diractin
Novel drug target	Established target
Trial Name	ketoprofen transdermal patch, EN3269

Trial Name	HZT-501, ibuprofen + famotidine,Duexa
Novel drug target	Established target
Mechanism of Interaction	Cyclooxygenase inhibitor

Trial Name	MAX-002
Novel drug target	Established target
Trial Name	mesalamine,Pentasa, Canasa, Asacol

PROSTAGLANDIN G/H SYNTHASE 1 PRECURSOR (EC 1.14.99.1) (CYCLOOXYGENASE- 1) (COX-1) (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1) (PROSTAGLANDIN H2 SYNTHASE 1) (PGH SYNTHASE 1) (PGHS-1) (PHS 1). [SOURCE:UNIPROT/SWISSPROT;ACC:P23219]	Description
ENSG00000095303	Ensembl Gene Id
PTGS1	Display Id

9604	HUGO Gene ID
9604	HUGO Gene Symbol
prostaglandin-endoperoxide synthase 1	HUGO Gene Name

PTGS1	DrugBank Gene Name
P23219	UniProt Accession
5742	Entrez Gene Id

COX1	GENE_SYMBOL
PTGS1	GENE_SYMBOL
Prostaglandin G/H synthase 1	UNIPROT

PTGS1 Gene Record

PTGS1 5742 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclooxygenase inhibitor Direct Interaction yes Specific Action of the Ligand Inhibition

PMIDs: 11885959 11752352 17477341 10377455 8652509

Sources: TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10592235 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10592235 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: 1680855 10452868 11752352 15242723

Sources: TEND TdgClinicalTrial TTD DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 16190133 11939906 11477109 15990700 11752352 11121413

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Bromfenac Novel drug target Established target Trial Name ISV-101

PMIDs: 16846546 11752352

Sources: TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 16961726 16144976

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 15035793 15840771 14746879 16368818 15871445

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name ketorolac tromethamine ophthalmic solution,Acuvail Novel drug target Established target Trial Name ROX-828

PMIDs: 11695255 16262557 10220509 16277613 10422661

Sources: TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 19338579 9831331 15324530 19952416 17024689

Sources: DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclooxygenase inhibitor Direct Interaction yes Trial Name -

PMIDs: 10850857

Sources: TEND TdgClinicalTrial DrugBank ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 14613550 10465690 9253954 16182428

Sources: TEND TdgClinicalTrial DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10592235

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10592235

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 14680616 2083404 17131625

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10592235

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 17541796 6342700 7088753

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name VT-122 Novel drug target Established target

PMIDs: 8566109 9146894 12358053 16473424 15198222

Sources: TEND TdgClinicalTrial DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name balsalazide disodium,Colazal, Giazo

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
11885959 11752352 17477341 10377455 8652509

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
10592235 17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
10592235 17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
1680855 10452868 11752352 15242723

Sources:
TEND TdgClinicalTrial TTD DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16190133 11939906 11477109 15990700 11752352 11121413

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Bromfenac

Novel drug target Established target

Trial Name ISV-101

PMIDs:
16846546 11752352

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16961726 16144976

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
15035793 15840771 14746879 16368818 15871445

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ketorolac tromethamine ophthalmic solution,Acuvail

Novel drug target Established target

Trial Name ROX-828

PMIDs:
11695255 16262557 10220509 16277613 10422661

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
19338579 9831331 15324530 19952416 17024689

Sources:
DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
10850857

Sources:
TEND TdgClinicalTrial DrugBank ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
14613550 10465690 9253954 16182428

Sources:
TEND TdgClinicalTrial DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
10592235

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
10592235

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
14680616 2083404 17131625

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
10592235

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
17541796 6342700 7088753

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name VT-122

Novel drug target Established target

PMIDs:
8566109 9146894 12358053 16473424 15198222

Sources:
TEND TdgClinicalTrial DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name balsalazide disodium,Colazal, Giazo

PMIDs:
12950415 11752352 17139284 17016423 19743890

Sources:
TdgClinicalTrial TTD DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclooxygenase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
11811354 10358065 10773011 12392782 17562170 12711844 19066416

Sources:
TEND DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
14987823 14741265 15575422 14592549

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ketoprofen in Transfersome gel, IDEA-033,Diractin

Novel drug target Established target

Trial Name ketoprofen transdermal patch, EN3269

PMIDs:
11811354 14987823 14513718 10929089 15476667

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17017983 11563332 9175172 9152412 15943176